Suit Against Drug Research Firm Allowed to Continue

Breaking new ground in drug products liability, a federal judge has refused to dismiss negligence and fraud claims against a research firm that allegedly conspired with a drug maker to mislead the FDA. The judge rejected the argument that the firm owes no duty of care to a patient who was harmed by a drug that won FDA approval due to falsified test results. The judge also concluded the plaintiff's state tort claims were not pre-empted by federal law because the drug maker pleaded guilty to criminal fraud.

This article requires premium access

This article requires premium access to Law.com. Please sign in or subscribe to read the full text.